Clinical trial
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT…
NCT00461591 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00461591 |
|---|---|
| Title | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611) |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Apaziquone, Placebo, TURBT |
| Enrollment | 802 |
| Start date | Apr 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Apr 18, 2007 |
| Last update posted | Mar 30, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: